Latest news and press releases about ABVC BioPharma, Inc. (ABVC): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer.
Price
| Price | $1.08 |
| Market Cap | $28M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.18 |
| EV / EBITDA | -7.04 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -71.17% |
| Return on Invested Capital | -42.64% |
| Return on Assets | -37.55% |
| Gross Margin | 100.00% |
| Operating Margin | 918.55% |
| Net Margin | 992.85% |
Related companies: ATNM · FGEN · GRCE · JUNS · LTRN · LVTX · PDSB
Explore sector: Healthcare · Biotechnology
More sections of ABVC: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks